GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines, vaccines and consumer healthcare products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. The Consumer Healthcare business develops and markets products in Wellness, Oral health, Nutrition and Skin health categories. Its product portfolio includes Adartrel, Bexsero, Daraprim and Quinvaxem. Its brands include Panadol, abreva, polident and physiogel.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Pharmaceuticals - NEC
- Sub-Industry: N/A
- Symbol: NYSE:GSK
- CUSIP: N/A
- Web: www.gsk.com
Capitalization:- Market Cap: $96.50058 billion
- Outstanding Shares: 2,459,239,000
Average Prices:- 50 Day Moving Avg: $41.27
- 200 Day Moving Avg: $41.84
- 52 Week Range: $37.20 - $44.58
P/E:- Trailing P/E Ratio: 37.77
- Foreward P/E Ratio: 13.33
- P/E Growth: 1.10
Sales & Book Value:- Annual Revenue: $39.4 billion
- Price / Sales: 2.44
- Book Value: $0.44 per share
- Price / Book: 88.75
Dividend:- Annual Dividend: $1.97
- Dividend Yield: 5.0%
Profitability:- EBIDTA: $10.77 billion
- Net Margins: 6.48%
- Return on Equity: 114.93%
- Return on Assets: 9.25%
Debt:- Debt-to-Equity Ratio: 2.77%
- Current Ratio: 0.57%
- Quick Ratio: 0.37%
Misc:- Average Volume: 2.77 million shs.
- Beta: 1.03
- Short Ratio: 1.71
Frequently Asked Questions for GlaxoSmithKline PLC (NYSE:GSK)
What is GlaxoSmithKline PLC's stock symbol?
GlaxoSmithKline PLC trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."
How often does GlaxoSmithKline PLC pay dividends? What is the dividend yield for GlaxoSmithKline PLC?
GlaxoSmithKline PLC announced a quarterly dividend on Wednesday, July 26th. Shareholders of record on Friday, August 11th will be given a dividend of $0.491 per share on Thursday, October 12th. This represents a $1.96 annualized dividend and a yield of 5.03%. The ex-dividend date of this dividend is Wednesday, August 9th. This is a boost from GlaxoSmithKline PLC's previous quarterly dividend of $0.46. View GlaxoSmithKline PLC's Dividend History.
How were GlaxoSmithKline PLC's earnings last quarter?
GlaxoSmithKline PLC (NYSE:GSK) issued its earnings results on Wednesday, July, 26th. The company reported $0.70 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.68 by $0.02. The company had revenue of $9.36 billion for the quarter, compared to the consensus estimate of $9.52 billion. GlaxoSmithKline PLC had a net margin of 6.48% and a return on equity of 114.93%. View GlaxoSmithKline PLC's Earnings History.
When will GlaxoSmithKline PLC make its next earnings announcement?
Where is GlaxoSmithKline PLC's stock going? Where will GlaxoSmithKline PLC's stock price be in 2017?
16 brokers have issued 12 month price objectives for GlaxoSmithKline PLC's shares. Their forecasts range from $37.00 to $50.00. On average, they anticipate GlaxoSmithKline PLC's stock price to reach $43.50 in the next twelve months. View Analyst Ratings for GlaxoSmithKline PLC.
Who are some of GlaxoSmithKline PLC's key competitors?
Some companies that are related to GlaxoSmithKline PLC include Merck & Company (MRK), Sanofi (SNY), Novo Nordisk A/S (NVO), Bristol-Myers Squibb Company (BMY), Eli Lilly and Company (LLY), Abbott Laboratories (ABT), Astrazeneca PLC (AZN), AstraZeneca plc (AZN), Shire PLC (SHPG), Shire PLC (SHP), Teva Pharmaceutical Industries Limited (TEVA), Dr. Reddy's Laboratories Ltd (RDY), Patheon NV (PTHN), Valeant Pharmaceuticals International (VRX), Catalent (CTLT), Akorn (AKRX), Taro Pharmaceutical Industries (TARO) and Opko Health (OPK).
Who are GlaxoSmithKline PLC's key executives?
GlaxoSmithKline PLC's management team includes the folowing people:
- Emma Walmsley, Chief Executive Officer - Designate, Executive Director
- Simon Dingemans, Chief Financial Officer, Executive Director
- Patrick Vallance, President - Pharmaceuticals R&D, Executive Director
- Roger Connor, President - Global Manufacturing & Supply
- Abbas Hussain, President - Global Pharmaceuticals
- Shah Abbas Hussain, President - Global Pharmaceuticals
- Luke Miels, President - Global Pharmaceuticals
- Daniel E Troy, Senior Vice President, General Counsel
- Claire Thomas, Senior Vice President - Human Resources
- Nick Hirons, Senior Vice President – Global Ethics and Compliance
Who owns GlaxoSmithKline PLC stock?
GlaxoSmithKline PLC's stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (1.02%), Fisher Asset Management LLC (0.51%), State Street Corp (0.42%), Renaissance Technologies LLC (0.38%), Hotchkis & Wiley Capital Management LLC (0.32%) and Bank of New York Mellon Corp (0.24%). View Institutional Ownership Trends for GlaxoSmithKline PLC.
Who sold GlaxoSmithKline PLC stock? Who is selling GlaxoSmithKline PLC stock?
GlaxoSmithKline PLC's stock was sold by a variety of institutional investors in the last quarter, including Arrowstreet Capital Limited Partnership, Ameriprise Financial Inc., Miller Howard Investments Inc. NY, Schafer Cullen Capital Management Inc., Equity Investment Corp Acquisition Inc, State Street Corp, JPMorgan Chase & Co. and Eaton Vance Management. View Insider Buying and Selling for GlaxoSmithKline PLC.
Who bought GlaxoSmithKline PLC stock? Who is buying GlaxoSmithKline PLC stock?
GlaxoSmithKline PLC's stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, FMR LLC, Federated Investors Inc. PA, Marshall Wace North America L.P., Fisher Asset Management LLC, Sphera Funds Management LTD., Hotchkis & Wiley Capital Management LLC and Parametric Portfolio Associates LLC. View Insider Buying and Selling for GlaxoSmithKline PLC.
How do I buy GlaxoSmithKline PLC stock?
Shares of GlaxoSmithKline PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is GlaxoSmithKline PLC's stock price today?
One share of GlaxoSmithKline PLC stock can currently be purchased for approximately $39.05.
MarketBeat Community Rating for GlaxoSmithKline PLC (NYSE GSK)MarketBeat's community ratings are surveys of what our community members think about GlaxoSmithKline PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for GlaxoSmithKline PLC (NYSE:GSK) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Sell Rating, 6 Hold Ratings, 9 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.50) |
| Consensus Price Target: | $43.50 (11.40% upside) |
Analysts' Ratings History for GlaxoSmithKline PLC (NYSE:GSK)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/27/2017 | Citigroup Inc. | Reiterated Rating | Neutral | | Low |  |
| 7/24/2017 | J P Morgan Chase & Co | Reiterated Rating | Neutral | | Low | |
| 5/26/2017 | Berenberg Bank | Upgrade | Hold -> Buy | | Low | |
| 4/6/2017 | BNP Paribas | Lower Price Target | | $37.00 | Low | |
| 4/5/2017 | Exane BNP Paribas | Upgrade | Underperform -> Neutral | | Low | |
| 3/9/2017 | Liberum Capital | Initiated Coverage | Buy -> Buy | | Low | |
| 3/9/2017 | Kepler Capital Markets | Initiated Coverage | Reduce -> Reduce | | Low | |
| 3/7/2017 | Barclays PLC | Initiated Coverage | Equal Weight | | N/A | |
| 2/19/2017 | Jefferies Group LLC | Reiterated Rating | Buy | | N/A | |
| 2/9/2017 | Deutsche Bank AG | Reiterated Rating | Neutral | | N/A | |
| 12/27/2016 | Goldman Sachs Group, Inc. (The) | Reiterated Rating | Buy | | N/A | |
| 10/26/2016 | Beaufort Securities | Reiterated Rating | Buy | | N/A | |
| 10/20/2016 | Investec | Initiated Coverage | Buy | | N/A | |
| 9/23/2016 | Piper Jaffray Companies | Initiated Coverage | Overweight | | N/A | |
| 9/20/2016 | Bank of America Corporation | Reiterated Rating | Buy | $50.00 | N/A | |
| 9/12/2016 | HSBC Holdings plc | Reiterated Rating | Buy | | N/A | |
| 8/17/2016 | Shore Capital | Reiterated Rating | Hold | | N/A | |
| 8/12/2016 | Argus | Boost Price Target | Buy | $48.00 -> $50.00 | N/A | |
| 5/26/2016 | Cowen and Company | Downgrade | Outperform -> Market Perform | | N/A | |
| 5/5/2016 | Oddo Securities | Upgrade | Reduce -> Buy | | N/A | |
| 2/26/2016 | Cantor Fitzgerald | Initiated Coverage | Hold | | N/A | |
| 2/4/2016 | Sanford C. Bernstein | Boost Price Target | Market Perform | $43.00 -> $45.00 | N/A | |
| 1/27/2016 | Bryan, Garnier & Co | Upgrade | Neutral -> Buy | | N/A | |
| 12/21/2015 | Leerink Swann | Reiterated Rating | Market Perform | $48.00 | N/A | |
| 11/6/2015 | Morgan Stanley | Reiterated Rating | Neutral | | N/A | |
| 10/31/2015 | Societe Generale | Reiterated Rating | Sell | | N/A | |
| 10/20/2015 | Credit Suisse Group | Upgrade | Underperform -> Neutral | | N/A | |
(Data available from 8/18/2015 forward)
Earnings History for GlaxoSmithKline PLC (NYSE:GSK)Earnings History by Quarter for GlaxoSmithKline PLC (NYSE GSK)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/25/2017 | | | | | | | | |
| 7/26/2017 | 6/30/2017 | $0.68 | $0.70 | $9.52 billion | $9.36 billion | View | N/A | |
| 4/26/2017 | 3/31/2017 | $0.62 | $0.62 | $9.09 billion | $9.23 billion | View | N/A | |
| 2/8/2017 | 12/31/2016 | $0.57 | $0.65 | $9.21 billion | $9.43 billion | View | Listen | |
| 10/26/2016 | Q316 | $0.77 | $0.83 | $8.92 billion | $9.90 billion | View | Listen | |
| 10/28/2015 | Q3 | $0.60 | $0.71 | $6.07 billion | $6.13 billion | View | N/A | |
| 7/29/2015 | Q215 | $0.50 | $0.53 | $9.14 billion | $9.02 billion | View | N/A | |
| 5/6/2015 | Q115 | $0.55 | $0.48 | $8.55 billion | $8.51 billion | View | N/A | |
| 2/4/2015 | Q414 | $0.86 | $0.82 | $6.14 billion | $6.19 billion | View | N/A | |
| 10/22/2014 | Q314 | $0.79 | $0.90 | $9.76 billion | $9.12 billion | View | Listen | |
| 7/23/2014 | Q114 | $0.71 | $0.65 | $10.13 billion | $9.47 billion | View | N/A | |
| 4/30/2014 | Q413 | $0.72 | $0.70 | $10.36 billion | $9.44 billion | View | N/A | |
| 2/5/2014 | Q4 | $0.30 | $0.30 | $6.84 billion | $6.91 billion | View | N/A | |
| 10/23/2013 | Q313 | | $0.31 | $10.31 billion | $10.09 billion | View | N/A | |
| 7/24/2013 | | $0.26 | $0.26 | | $6.62 billion | View | N/A | |
| 4/25/2012 | | $0.29 | $0.27 | | | View | N/A | |
| 2/7/2012 | | $0.30 | $0.28 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for GlaxoSmithKline PLC (NYSE:GSK)2017 EPS Consensus Estimate: $2.88
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | $0.59 | $0.63 | $0.61 |
| Q2 2017 | 1 | $0.71 | $0.71 | $0.71 |
| Q3 2017 | 1 | $0.81 | $0.81 | $0.81 |
| Q4 2017 | 1 | $0.75 | $0.75 | $0.75 |
(Data provided by Zacks Investment Research)
Current Dividend Information for GlaxoSmithKline PLC (NYSE:GSK)| Next Dividend: | 10/12/2017 |
| Annual Dividend: | $1.97 |
| Dividend Yield: | 5.04% |
| Dividend Growth: | -3.10% (3 Year Average) |
| Payout Ratio: | 197.00% (Trailing 12 Months of Earnings)
69.12% (Based on This Year's Estimates)
67.24% (Based on Next Year's Estimates)
|
Dividend History by Quarter for GlaxoSmithKline PLC (NYSE GSK)| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 7/26/2017 | Quarterly | $0.49 | 4.88% | 8/9/2017 | 8/11/2017 | 10/12/2017 |
| 4/26/2017 | quarterly | $0.48 | 4.79% | 5/10/2017 | 5/12/2017 | 7/13/2017 |
| 2/8/2017 | quarterly | $0.57 | 5.76% | 2/22/2017 | 2/24/2017 | 4/13/2017 |
| 10/26/2016 | | $0.46 | | 11/2/2016 | 11/4/2016 | 1/12/2017 |
| 7/27/2016 | | $0.49 | | 8/10/2016 | 8/12/2016 | 10/13/2016 |
| 4/28/2016 | | $0.55 | | 5/11/2016 | 5/13/2016 | 7/14/2016 |
| 10/28/2015 | | $0.58 | | 11/10/2015 | 11/13/2015 | 1/14/2016 |
| 5/7/2015 | quarterly | $0.58 | 5.22% | 5/13/2015 | 5/15/2015 | 7/9/2015 |
| 2/5/2015 | quarterly | $0.70 | 6.05% | 2/18/2015 | 2/20/2015 | 4/9/2015 |
| 10/23/2014 | quarterly | $0.61 | 5.41% | 11/5/2014 | 11/7/2014 | 1/8/2015 |
| 7/24/2014 | quarterly | $0.65 | 5.18% | 8/6/2014 | 8/8/2014 | 10/2/2014 |
| 5/1/2014 | quarterly | $0.64 | 4.62% | 5/14/2014 | 5/16/2014 | 7/10/2014 |
| 2/5/2014 | | $0.75 | | 2/19/2014 | 2/21/2014 | 4/10/2014 |
| 2/6/2014 | quarterly | $0.75 | 5.73% | 2/19/2014 | 2/21/2014 | 4/10/2014 |
| 10/24/2013 | quarterly | $0.62 | 4.76% | 11/13/2013 | 11/15/2013 | 1/9/2014 |
| 7/25/2013 | quarterly | $0.55 | 4.27% | 8/7/2013 | 8/9/2013 | 10/3/2013 |
| 4/25/2013 | quarterly | $0.55 | 4.25% | 5/8/2013 | 5/10/2013 | 7/11/2013 |
| 2/7/2013 | quarterly | $0.07 | 0.61% | 2/20/2013 | 2/22/2013 | 4/11/2013 |
(Data available from 1/1/2013 forward)
Insider Trading and Institutional Ownership History for GlaxoSmithKline PLC (NYSE:GSK)Insider Ownership Percentage: 10.00%
Institutional Ownership Percentage: 8.99%
Insider Trades by Quarter for GlaxoSmithKline PLC (NYSE:GSK)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 10/24/2016 | Plc Glaxosmithkline | Major Shareholder | Buy | 66,500 | $14.00 | $931,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for GlaxoSmithKline PLC (NYSE:GSK)
Latest Headlines for GlaxoSmithKline PLC (NYSE:GSK)
| Source: |
|
| Date | Headline |
|---|
 | Shire Gains as it Seeks European Approval For Dry Eye Treatment - TheStreet.com
www.thestreet.com - August 15 at 5:42 AM |
 | Shire Gains as it Seeks European Approval For Dry Eye Treatment
finance.yahoo.com - August 15 at 5:42 AM |
| What Happened In Biotech Last Week?
finance.yahoo.com - August 14 at 7:37 PM |
| [$$] The key to innovation is balancing risk and rigour
finance.yahoo.com - August 14 at 7:37 PM |
| Where Does Zika Virus Vaccine Research Stand Now?
finance.yahoo.com - August 12 at 6:22 PM |
| Biotech movers: Ionis Drops After GSK Bows Out of Partnership - TheStreet.com
www.thestreet.com - August 12 at 12:45 AM |
 | Ionis Retains All Rights To Inotersen, IONIS-FB-L Rx; GSK Declines Its Options
www.rttnews.com - August 11 at 7:42 PM |
| ETFs with exposure to GlaxoSmithKline Plc : August 11, 2017
finance.yahoo.com - August 11 at 7:42 PM |
| UK fraud office expects decision on GSK, Rolls-Royce cases next year
finance.yahoo.com - August 11 at 1:32 AM |
 | VEU, TOT, RY, GSK: Large Inflows Detected at ETF - Nasdaq
www.nasdaq.com - August 9 at 7:26 PM |
| Former GSK exec resigns from Intellia board due to 'conflict'
finance.yahoo.com - August 9 at 7:26 PM |
| Mexico watchdog finds big pharma faces no competition on some drugs
finance.yahoo.com - August 9 at 7:26 PM |
| [$$] Blockbuster drugs depend on marketing, not design
finance.yahoo.com - August 9 at 7:26 PM |
 | GlaxoSmithKline PLC (NYSE:GSK) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - August 8 at 8:40 PM |
| Drugmakers' hopes for gene therapy rise despite tiny sales in Europe
finance.yahoo.com - August 8 at 6:58 PM |
| [$$] GSK chief says her lack of 'baggage' in pharma is an advantage
finance.yahoo.com - August 6 at 5:55 PM |
| [$$] GSK chief vows to stop 'drifting off in hobbyland' with R&D
finance.yahoo.com - August 6 at 5:55 PM |
 | Analysts say a United Therapeutics sale is premature
www.bizjournals.com - August 4 at 7:29 PM |
| GlaxoSmithKline’s 2Q17 Earnings: Business Segments
finance.yahoo.com - August 1 at 7:47 PM |
| GSK’s 2Q17 Earnings: Pharmaceuticals Segment
finance.yahoo.com - August 1 at 7:47 PM |
| How Gilead Sciences Performed in 2Q17
finance.yahoo.com - August 1 at 7:47 PM |
| August PDUFA Dates: Biotech Investors Stay Tuned To A Month Of Plenty
finance.yahoo.com - August 1 at 7:47 PM |
| GlaxoSmithKline’s 2Q17 Earnings: HIV Business
finance.yahoo.com - August 1 at 7:47 PM |
 | J&J arthritis drug sirukumab raises safety concerns: FDA staff - Reuters
www.reuters.com - August 1 at 4:54 AM |
| Former Walmart CIO Named Chief Digital And Technology Officer Of GlaxoSmithKline
finance.yahoo.com - July 31 at 6:50 PM |
| 8 Of The Biggest Whistles Ever Blown On Wall Street
finance.yahoo.com - July 31 at 6:50 PM |
| J&J arthritis drug sirukumab raises safety concerns -FDA staff
finance.yahoo.com - July 31 at 6:50 PM |
| GlaxoSmithKline’s 2Q17 Earnings Reveal Growth
finance.yahoo.com - July 31 at 6:50 PM |
| Foreign Stock Roundup: GSK, Shell, AstraZeneca Beat on Earnings
finance.yahoo.com - July 31 at 6:50 PM |
| Leerink Swann Research Analysts Cut Earnings Estimates for GlaxoSmithKline PLC (NYSE:GSK)
www.americanbankingnews.com - July 31 at 8:31 AM |
| GlaxoSmithKline PLC (GSK) Downgraded to "C+" at TheStreet
www.americanbankingnews.com - July 30 at 8:32 PM |
| GlaxoSmithKline Plc :GSK-US: Earnings Analysis: Q2, 2017 By the Numbers : July 28, 2017
finance.yahoo.com - July 29 at 11:12 PM |
| Interesting GSK Put And Call Options For June 2018 - Nasdaq.com - Nasdaq
www.nasdaq.com - July 28 at 9:54 PM |
| GlaxoSmithKline (GSK) Beats on Q2 Earnings, Lowers Guidance - Nasdaq
www.nasdaq.com - July 28 at 9:54 PM |
| Leerink Swann Analysts Cut Earnings Estimates for GlaxoSmithKline PLC (NYSE:GSK)
www.americanbankingnews.com - July 28 at 7:28 AM |
| GlaxoSmithKline PLC (NYSE:GSK) Announces Earnings Results
www.americanbankingnews.com - July 27 at 9:08 PM |
| Overhaul Drug R&D? Easier Said Than Done
finance.yahoo.com - July 27 at 7:48 PM |
| GlaxoSmithKline Capital Inc. -- Moody's changes outlook on GSK's A2 rating to stable from negative; affirms ratings
finance.yahoo.com - July 27 at 7:48 PM |
| GlaxoSmithKline PLC's (NYSE:GSK) "Neutral" Rating Reiterated at Citigroup Inc.
www.americanbankingnews.com - July 27 at 2:05 PM |
| GlaxoSmithKline PLC (NYSE:GSK) Plans Dividend Increase - $0.49 Per Share
www.americanbankingnews.com - July 27 at 11:17 AM |
| Drugmaker GSK calls for at least two years' Brexit transition
finance.yahoo.com - July 27 at 5:54 AM |
| Glaxo CFO Says Prioritizing R&D for Product Growth
finance.yahoo.com - July 27 at 5:54 AM |
| Glaxo Looks Beyond the Lab
finance.yahoo.com - July 27 at 5:54 AM |
| GSK gives up on rare diseases as gene therapy gets two customers
finance.yahoo.com - July 27 at 5:54 AM |
| GlaxoSmithKline is Now Oversold (GSK) - Nasdaq
www.nasdaq.com - July 26 at 7:50 PM |
| Glaxo reports 2Q loss
finance.yahoo.com - July 26 at 7:50 PM |
| [$$] Glaxo Slashes R&D Projects to Focus on Top Prospects
finance.yahoo.com - July 26 at 7:50 PM |
| $9.52 Billion in Sales Expected for GlaxoSmithKline PLC (GSK) This Quarter
www.americanbankingnews.com - July 26 at 12:01 PM |
| Analysts’ Recommendations for Merck in July 2017
finance.yahoo.com - July 25 at 7:34 PM |
| Corporate News Blog - GlaxoSmithKline and Innoviva Submits EU Filing for Extended Use of Relvar Ellipta in Patients with Controlled Asthma
finance.yahoo.com - July 25 at 7:34 PM |
GlaxoSmithKline PLC (GSK) Chart for Friday, August, 18, 2017
